唾液1,5-脱水葡萄糖醇正常值的建立及临床应用

注册号:

Registration number:

ChiCTR-SOC-17011356 

最近更新日期:

Date of Last Refreshed on:

2017-05-11 21:43:37 

注册时间:

Date of Registration:

2017-05-11 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

唾液1,5-脱水葡萄糖醇正常值的建立及临床应用

Public title:

Identification and clinical application of nomal value of 1,5-anhydroglucitol in saliva

注册题目简写:

English Acronym:

研究课题的正式科学名称:

唾液1,5-脱水葡萄糖醇正常值的建立及临床应用

Scientific title:

Identification and clinical application of nomal value of 1,5-anhydroglucitol in saliva

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

包玉倩 

研究负责人:

包玉倩 

Applicant:

Yuqian Bao 

Study leader:

Yuqian Bao 

申请注册联系人电话:

Applicant telephone:

+86 13788971763

研究负责人电话:

Study leader's
telephone:

+86 13788971763

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

byq522@163.com

研究负责人电子邮件:

Study leader's E-mail:

byq522@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市宜山路600号

研究负责人通讯地址:

上海市宜山路600号

Applicant address:

600 Yishan Road, Shanghai

Study leader's address:

600 Yishan Road, Shanghai

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

上海交通大学附属第六人民医院内分泌代谢科

Applicant's institution:

Department of Endocrinology and Metabolism, Shanghai Jiaotong University Affiliated Sixth Peoplel‘s Hospital

研究负责人所在单位:

上海交通大学附属第六人民医院内分泌代谢科

Affiliation of the Leader:

Department of Endocrinology and Metabolism, Shanghai Jiaotong University Affiliated Sixth Peoplel‘s Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SH6THHOSP-KY-2017-038

伦理委员会批件附件:

Approved file of Ethical Committee:

批准本研究的伦理委员会名称:

上海市第六人民医院伦理委员会

Name of the ethic committee:

Shanghai No Sixth People 's Hospital Ethics Committee

伦理委员会批准日期:

Date of approved by ethic committee:

1990-01-01 00:00:00

伦理委员会联系人:

Contact Name of the ethic committee:

伦理委员会联系地址:

Contact Address of the ethic committee:

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

上海交通大学附属第六人民医院内分泌代谢科

Primary sponsor:

Department of Endocrinology and Metabolism, Shanghai Jiaotong University Affiliated Sixth Peoplel‘s Hospital

研究实施负责(组长)单位地址:

上海市宜山路600号

Primary sponsor's address:

600 Yishan Road, Shanghai

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院

具体地址:

上海市宜山路600号

Institution
hospital:

Shanghai No. Sixth Peoplel‘s Hospital

Address:

600 Yishan Road, Shanghai

经费或物资来源:

市级医院新兴前沿技术联合攻关项目

Source(s) of funding:

Shanghai United Developing Technology Project of Municipal Hospitals

研究疾病:

糖尿病  

Target disease:

diabetes

研究疾病代码:

Target disease code:

研究类型:

筛查

Study type:

Screening

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

横断面 

Study design:

Cross-sectional 

研究目的:

建立唾液1,5-AG检测的标准化方法及质控体系,并在上海三级医院推广。通过多中心、大样本人群研究,建立1,5-AG的正常参考值,以及唾液1,5-AG与血糖及HbA1c的对应关系,以精确方法—动态血糖监测技术评价唾液1,5-AG估测餐后血糖波动的效率,为指导糖尿病个体化治疗提供新的有效方法。  

Objectives of Study:

Establish the standardized methods and quality control system of saliva 1,5-AG, and promote the methods in Shanghai municipal hospitals. The normal reference values of 1,5-AG and the correspondence between saliva 1,5-AG and blood glucose and HbA1c were established by multi-center and large sample population. The saliva 1,5-AG was evaluated by precise method-continuous blood glucose monitoring system to estimate the efficiency of postprandial blood glucose fluctuations, to guide the individual treatment of diabetes and provide an effective method.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

①试验前1个月内及试验中使用过可能影响糖代谢的药物如糖皮质激素、甲状腺激素、噻嗪类利尿剂等。
②肝、肾功能障碍(丙氨酸氨基转移酶或天冬氨酸氨基转移酶或直接胆红素高于正常上限的1.5倍,或血肌酐 > 115 μmol/L)。
③妊娠、肿瘤及精神疾患。
④存在影响体内1,5-AG 水平的因素如囊性纤维化、胃大部切除术后、服用某些中药如远志、美远志等。

Exclusion criteria:

1. using drugs may affect the metabolism of glucose such as glucocorticoids, thyroid hormones, thiazide diuretics 1 month before the test;
2. liver and kidney dysfunction (alanine aminotransferase or aspartate aminotransferase or direct bilirubin higher than the normal upper limit of 1.5 times, or serum creatinine> 115umol/L);
3. pregnancy, cancer and mental illness;
4. affecting the body 1,5-AG levels such as cystic fibrosis, gastrectomy, taking some traditional Chinese medicine such as Polygalaceae, the US Polygalaceae.

研究实施时间:

Study execute time:

From 2016-10-01 00:00:00 To 2019-09-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2017-06-01 00:00:00 To 2018-09-30 00:00:00

干预措施:

Interventions:

组别:

样本量:

3000

Group:

None

Sample size:

干预措施:

干预措施代码:

Intervention:

None

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China

Province:

Shanghai

City:

单位(医院):

上海市第六人民医院 

单位级别:

三甲医院 

Institution
hospital:

Shanghai No. Sixth Peoplel‘s Hospital

Level of the institution:

Tertiary A hospital

测量指标:

Outcomes:

指标中文名:

唾液1,5-AG

指标类型:

主要指标

Outcome:

Saliva 1,5-AG

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

主要指标

Outcome:

Glucos concentration

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

HbA1c

指标类型:

主要指标

Outcome:

HbA1c

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

唾液

组织:

Sample Name:

saliva

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

血液

组织:

Sample Name:

blood

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

标本中文名:

尿液

组织:

Sample Name:

Urine

Tissue:

人体标本去向

使用后保存  

说明

Fate of sample:

Preservation after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

Blinding:

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

试验完成6个月内,上传到临床试验公共管理平台 Clinical Trial Management Public Platform(http://www.medresman.org/pub/cn/proj/search.aspx)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Within 6 months while the trial was completed the data will be uploaded to the Clinical Trial Management Public Platform (http://www.medresman.org/pub/cn/proj/search.aspx)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

每位受试者的原始数据记录于调查问卷,通过excel/epidata进行数据保存

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The original data for each subject is recorded in the questionnaire and the data is saved by excel / epidata.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

注册人:

Name of Registration:

 2017-05-11 21:43:37